双基因型Alport综合征
双基因型Alport综合征指COL4A5与COL4A3或COL4A4,或COL4A3与COL4A4同时存在致病性变异。累及COL4A5时,男性所有IV型胶原α3α4α5异源三聚体均受累,额外COL4A3或COL4A4变异可能不加重病情;女性平均50%异源三聚体受累,额外变异增至75%并增加蛋白尿风险。COL4A3与COL4A4双变异时75%异源三聚体受累,顺式遗传为常染色体显性,反式遗传为常染色体隐性,中位肾衰竭年龄介于常染色体显性与隐性Alport综合征之间。
要点
- COL4A5致病变异男性所有异源三聚体受累,额外COL4A3或COL4A4变异可能不加重病情。
- COL4A5致病变异女性平均50%异源三聚体受累,额外变异增至75%并增加蛋白尿风险。
- COL4A3与COL4A4双变异顺式遗传为常染色体显性,反式遗传为常染色体隐性。
核心结论
- 双基因型Alport综合征的后果取决于性别、COL4A5变异严重程度及COL4A3或COL4A4变异的性质。
- COL4A3与COL4A4双变异导致蛋白尿增加,中位肾衰竭年龄介于常染色体显性与隐性Alport综合征之间。
- 既往指南建议所有致病性或可能致病性双基因变异均应被识别和报告。
- 受累家庭成员应被识别、治疗,并劝阻其捐献肾脏。
研究设计与样本
- 综述,探讨双基因型Alport综合征的遗传机制与临床后果。
主要发现
- COL4A5致病变异男性所有IV型胶原α3α4α5异源三聚体均受累,额外COL4A3或COL4A4变异可能不加重病情。
- COL4A5致病变异女性平均50%异源三聚体受累,额外COL4A3或COL4A4变异增至75%并增加蛋白尿风险。
- COL4A3与COL4A4双变异时75%异源三聚体受累,顺式遗传为常染色体显性,反式遗传为常染色体隐性。
- COL4A3与COL4A4双变异导致蛋白尿增加,中位肾衰竭年龄介于常染色体显性与隐性Alport综合征之间。
关键数值与推荐
- COL4A5致病变异女性平均50%异源三聚体受累,额外COL4A3或COL4A4变异增至75%并增加蛋白尿风险。
- COL4A3与COL4A4双变异时75%异源三聚体受累,顺式遗传为常染色体显性,反式遗传为常染色体隐性。
- 既往指南建议所有致病性或可能致病性双基因变异均应被识别和报告。
临床怎么用
- 受累家庭成员应被识别、治疗,并劝阻其捐献肾脏。
- 家族内遗传预测时,若分别考虑两个变异,并已知COL4A3与COL4A4变异位于同一或不同染色体,则更易预测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Digenic Alport syndrome refers to the inheritance of pathogenic variants in COL4A5 plus COL4A3 or COL4A4 or in COL4A3 plus COL4A4 Where digenic Alport syndrome includes a pathogenic COL4A5 variant, the consequences depend on the sex of the affected individual, COL4A5 variant "severity," and the nature of the COL4A3 or COL4A4 change. A man with a pathogenic COL4A5 variant has all his collagen IV α3α4α5-heterotrimers affected, and an additional COL4A3 or COL4A4 variant may not worsen disease. A woman with a pathogenic COL4A5 variant has on average 50% of her heterotrimers affected, which is increased to 75% with a further COL4A3 or COL4A4 variant and associated with a higher risk of proteinuria. In digenic Alport syndrome with pathogenic COL4A3 and COL4A4 variants, 75% of the heterotrimers are affected. The COL4A3 and COL4A4 genes occur head-to-head on chromosome 2, and inheritance is autosomal dominant when both variants affect the same chromosome (in cis) or recessive when they affect different chromosomes (in trans). This form of digenic disease results in increased proteinuria and a median age of kidney failure intermediate between autosomal dominant and autosomal recessive Alport syndrome. Previous guidelines have suggested that all pathogenic or likely pathogenic digenic variants should be identified and reported. Affected family members should be identified, treated, and discouraged from kidney donation. Inheritance within a family is easier to predict if the two variants are considered independently and if COL4A3 and COL4A4 variants are known to be inherited on the same or different chromosomes.
引用
- Savige J, Renieri A, Ars E, et al. Digenic Alport Syndrome. Clin J Am Soc Nephrol. 2022. PMID: 35675912. doi:10.2215/CJN.03120322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。